Comparison of commercial and experimental porcine circovirus type 2 (PCV2) vaccines using a triple challenge with PCV2, porcine reproductive and respiratory syndrome virus (PRRSV), and porcine parvovirus (PPV).
The efficacies of commercial porcine circovirus type 2 (PCV2) vaccines and a live PCV1-2a chimeric vaccine were compared in conventional, PCV2-positive piglets using a PCV2-porcine reproductive and respiratory syndrome virus (PRRSV)-porcine parvovirus (PPV) coinfection challenge model. Seventy-three, 2-week-old pigs were randomized into seven groups including five vaccinated and two control groups. Pigs in the vaccinated groups were vaccinated at 3 weeks (one dose) or at 3 and 6 weeks (two dose) of age. All vaccine regimens tested were effective in reducing naturally occurring PCV2 viremia at 16 weeks of age and after PCV2 challenge, demonstrating the capability of the products to induce a lasting protective immunity despite the presence of PCV2 viremia at the time of vaccination.
Shen
H G
HG
Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.
Beach
N M
NM
Huang
Y W
YW
Halbur
P G
PG
Meng
X J
XJ
Opriessnig
T
T
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D018173:Circoviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D004279:DNA, Viral / Q000097:blood; D010322:Parvoviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D028323:Parvovirus, Porcine / Q000276:immunology; D019318:Porcine Reproductive and Respiratory Syndrome / Q000276:immunology / Q000517:prevention & control*; D019316:Porcine respiratory and reproductive syndrome virus / Q000276:immunology; D012367:RNA, Viral / Q000097:blood; D013552:Swine; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D004279:DNA, Viral; D012367:RNA, Viral; D014765:Viral Vaccines